Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CB-103
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Glenn J. Hanna
Deal Size : Inapplicable
Deal Type : Inapplicable
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Details : CB-103 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Adenoid Cystic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 20, 2023
Lead Product(s) : CB-103
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Glenn J. Hanna
Deal Size : Inapplicable
Deal Type : Inapplicable
CB-103 Plus NSAI In Luminal Advanced Breast Cancer
Details : CB-103 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 19, 2021
Lead Product(s) : CB-103
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CB-103 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2018
Lead Product(s) : CB-103
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
